TABLE 2.
Engraftment results
| Total enrolled | Not assessable specimens | Total assessable specimens | Engraftment rate of assessable specimens | Passageable tumors | Discontinued |
Not yet assessable: TG1 ongoing |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TG2/3 ongoing | TG3 established | Failed to grow in TG1 | Failed to grow in TG2 | Murine tumor | Lymphoma | ||||||
| Colorectal cancer | 258 | 258 | 36.4% | 21 | 73 | 50 | 11 | 2 | 71 | 30 | |
| Lung cancer | 245 | 3 | 242 | 22.7% | 21 | 34 | 85 | 8 | 1 | 24 | 69 |
| Breast cancer | 70 | 70 | 22.9% | 8 | 8 | 28 | 2 | 3 | 21 | ||
| Gastric cancer | 54 | 1 | 53 | 17.0% | 5 | 4 | 11 | 12 | 21 | ||
| Ovarian cancer | 31 | 31 | 22.6% | 5 | 2 | 3 | 2 | 19 | |||
| Pancreatic cancer | 29 | 1 | 28 | 57.1% | 2 | 14 | 7 | 1 | 2 | 2 | |
| Esophageal cancer | 26 | 2 | 24 | 37.5% | 4 | 5 | 8 | 2 | 5 | ||
| Bile duct cancer | 23 | 2 | 21 | 33.3% | 1 | 6 | 2 | 4 | 1 | 7 | |
| Uterine body cancer | 23 | 23 | 30.4% | 7 | 1 | 1 | 14 | ||||
| Uterine cervix cancer | 13 | 13 | 30.8% | 2 | 2 | 1 | 1 | 1 | 6 | ||
| Leukemia | 12 | 7 | 5 | 0.0% | 4 | 1 | |||||
| Gallbladder cancer | 11 | 1 | 10 | 40.0% | 4 | 2 | 4 | ||||
| Lymphoma | 9 | 1 | 8 | 12.5% | 1 | 5 | 2 | ||||
| Hepatocellular carcinoma | 7 | 7 | 14.3% | 1 | 1 | 5 | |||||
| Myeloma | 3 | 3 | 0 | 0.0% | |||||||
| Oropharyngeal cancer | 2 | 2 | 50.0% | 1 | 1 | ||||||
| Renal cell cancer | 2 | 2 | 50.0% | 1 | 1 | ||||||
| Bladder cancer | 1 | 1 | 100.0% | 1 | |||||||
| Thyroid cancer | 1 | 1 | 0.0% | 1 | |||||||
| Rare cancer/Sarcoma | 306 | 5 | 301 | 21.6% | 20 | 45 | 84 | 11 | 5 | 16 | 120 |
| Total | 1126 | 26 | 1100 | 27.1% | 97 | 201 | 290 | 39 | 10 | 137 | 326 |
Bold indicate the important values.